A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

December 13, 2021

The 63rd Annual ASH Meeting and Exposition

Screen Shot 2021-12-13 at 9.56.49 AM
Area of Focus
Oncology
Programs
Other
Indications
Other
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link